Literature DB >> 33471638

Prognostic Impact of Diabetes Mellitus on Overall Survival in a Nationwide Population-Based Cohort of Patients With Pancreatic Cancer.

Chao-Ming Tseng1, Hsi-Hao Wang2, Wen-Lun Wang3, Ching-Tai Lee3, Chi-Ming Tai3, Cheng-Hao Tseng1, Chih-Cheng Chen1, Ying-Nan Tsai1, Meng-Shun Sun4, Yao-Chun Hsu5.   

Abstract

OBJECTIVE: Diabetes mellitus (DM) is a risk factor for pancreatic cancer but its prognostic impact remains controversial. We aimed to investigate the association between long-standing DM and the risk of mortality.
METHODS: This population-based cohort study analyzed data from the national healthcare database in Taiwan. We identified all patients diagnosed with pancreatic cancer and excluded those who were diagnosed with DM with-in 2 years of the cancer diagnosis. Eligible patients were grouped into long-standing DM (>2 years) and nondiabetic controls, and were compared for overall survival using a Cox proportional hazard model. Sensitivity tests stratified by cancer stages (as indicated by specific treatment) were performed.
RESULTS: Patients with long-standing DM were significantly older (mean age, 71.38 years versus 66.0 years; P<.0001) and had a higher Charlson comorbidity index (9.53 versus 6.78; P<.0001) and diabetes comorbidity severity index (2.38 versus 0.82; P<.0001) compared with the non-DM controls. Although the unadjusted analysis showed a higher risk of mortality in the patients with long-term DM (crude hazard ratio &lsqb;HR], 1.26; 95% confidence interval &lsqb;CI], 1.20 to 1.33; P<.0001), the association became insignificant after adjustment for age, sex, and comorbidity index (adjusted HR, 1.01; 95% CI, 0.95 to 1.06, P = .84). Subgroup analyses also showed no association between long-term DM and mortality in various subgroups stratified by cancer treatment.
CONCLUSION: After adjusting for associated comorbidities and complications, long-standing DM per se was not an independent prognostic factor for overall survival in this nationwide population-based cohort with pancreatic cancer. ABBREVIATIONS: CCI = Charlson Comorbidity Index; CI = confidence interval; DCSI = Diabetes Complication Severity Index; DM = diabetes mellitus; HR = hazard ratio; ICD = International Classification of Diseases; NHIRD = National Health Insurance Research Database; RCIPD = Registry for Catastrophic Illness Patient Database.
© 2020 American Association of Clinical Endocrinologists. Published by Elsevier, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 33471638     DOI: 10.4158/EP-2019-0565

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  3 in total

1.  Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide.

Authors:  Yi-Ting Lin; Yen-Chun Huang; Chih-Kuan Liu; Tian-Shyug Lee; Mingchih Chen; Yu-Ning Chien
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.810

2.  Diabetes Mellitus and Pancreatic Ductal Adenocarcinoma-Prevalence, Clinicopathological Variables, and Clinical Outcomes.

Authors:  Anna Badowska-Kozakiewicz; Marta Fudalej; Daria Kwaśniewska; Marek Durlik; Anna Nasierowska-Guttmejer; Agata Mormul; Emilia Włoszek; Aleksandra Czerw; Tomasz Banaś; Andrzej Deptała
Journal:  Cancers (Basel)       Date:  2022-06-08       Impact factor: 6.575

3.  High Glucose Promotes Pancreatic Ductal Adenocarcinoma Gemcitabine Resistance and Invasion through Modulating ROS/MMP-3 Signaling Pathway.

Authors:  Junyuan Deng; Yujie Guo; Xiaomu Hu; Jiali Du; Jichun Gu; Lei Kong; Baian Tao; Deliang Fu; Tianlei Ying; Ji Li
Journal:  Oxid Med Cell Longev       Date:  2022-09-29       Impact factor: 7.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.